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REfERENCE PRICING fOR LAbORATORy TESTS IN THE UNITED STATES: IMPACT 
ON PRICES AND SPENDING
Robinson J, Brown T, Whaley C
University of California, Berkeley, Berkeley, CA, USA
Objectives: This study examines the impact of reference pricing on the price 
and spending for in vitro laboratory tests for a large private employer in the United 
States. MethOds: We obtained comprehensive laboratory and medical claims for 
employees of a major US firm from 2009 to 2013. Each claim contained the CPT code for 
the test, the price paid (allowed charge), and the identity and the location of the labora-
tory. We matched lab claims to medical claims for the patients, obtaining information 
on age, gender, diagnoses and co-morbidities (ICD9). Beginning in January 2011, the 
firm limited its payment for 566 in vitro laboratory tests to the 60th percentile in the 
price distribution for each test across national laboratories, hospital-based laboratories, 
and freestanding local laboratories. Reference-priced tests generated 99,225 individual 
patient assays and insurance claims. Another 247 types of in vitro tests were exempted 
from reference pricing; these generated 33,480 individual patient assays and insurance 
claims. We used difference-in-difference multivariable regression analysis (GLM with log 
link and gamma distribution) to measure the rate of change in prices paid per test for 
laboratory tests subject to reference pricing, compared to the change in prices paid for 
laboratory tests exempted from reference pricing. Results: Reference pricing led to a 
17.8% (p< .001) reduction in laboratory test prices paid in the first year after implementa-
tion. By the second year, this had increased to 21.6% (p< .001) and by the third year to a 
27.7% (p< .001) reduction. In the three years after implementation of reference pricing, 
the employer saved 18.5% in spending compared to what it would have spent had the 
prices of reference-priced tests continued to increase at the same rate as non-reference 
priced tests. cOnclusiOns: Reference pricing reduces prices paid per test and total 
spending on laboratory tests in the United States.
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THE ASSESSMENT Of VALUE fOR MEDICAL DEVICES: A CASE STUDy ON 
INjECTION TECHNIqUE EDUCATION IN INSULIN DELIVERy
Charter R1, Hopley C2, Su T3, Grima D3, Strauss K4
1Becton Dickinson AG, Allschwil, Switzerland, 2Becton Dickinson, Oxford, Switzerland, 
3Cornerstone Research Group, Burlington, ON, Canada, 4Becton Dickinson, Erembodegem, Belgium
Objectives: Education and product training are critical but overlooked variables in 
the value assessment of medical devices. By example, over 24 million insulin injec-
tions occur daily in Europe, with little knowledge on proper injection technique (IT).1 
This case study illustrates the positive impact of insulin IT education on diabetes 
outcomes, drug consumption and healthcare costs. MethOds: We conducted a 
literature review on diabetes IT. The impact of IT education on adherence, adverse 
events, insulin consumption, and glycemic control were appraised in the context 
of i) Proper device selection; ii) Education, application, and adherence to IT best 
practices; and; iii) adverse event monitoring. Potential healthcare savings from a 
UK NHS perspective were estimated using probabilistic patient simulations based 
on risk equations from the UKPDS study.2 Results: Evidence suggests the clinical 
benefits of IT best practices include 1) better patient acceptability via overall prefer-
ence and lower injection pain (VAS significantly less with shorter needle, sharper 
tips; p< 0.001)3 2), associations between not rotating injection sites (poor IT practice) 
and increased prevalence of lipohypertrophy, > 30% higher insulin consumption 
and worse glycaemic control4 (HbA1c 0.5% higher in patients with lipohypertrophy 
(p= 0.003)5, and 3), lower risk of intramuscular injections with proper device selec-
tion (0.4% – 1.8% for 4 and 5mm needles)6. Another prospective non-controlled 
study, investigating the impact of individualized IT education including site rotation 
and use of short needles, in patients taking insulin for more than 4 years, identified 
a mean HbA1c reduction of 0.58% and reduced insulin consumption by 2 units/day 
within 3 months (both, p< 0.05).7 Over 10 years, savings could range from £12-25 mil-
lion and potential insulin savings of £5 million per 100,000 people. cOnclusiOns: 
The value assessment of medical devices should include HCP/patient education as 
clinical outcomes and cost savings are material. This is exemplified vis-à-vis proper 
education on diabetes IT for people on insulin.
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HEALTHCARE ASSOCIATED INfECTIONS. IMPACT AND COSTS Of DIAGNOSIS 
AND MANAGEMENT Of CLOSTRIDIUM DIffICILE INfECTIONS (CDI). THE 
ExPERIENCE Of A UNIVERSITy HOSPITAL IN ROME
Capozzi C1, Fontana C2, Volpi A1, Lombardi G3, Lisena FP1, Paulon L1, Maurici M1, Visconti G2
1Tor Vergata University, Rome, Italy, 2Tor Vergata University Hospital, Rome, Italy, 3Rareg, Cesano 
Maderno, Italy
Objectives: The diagnosis and treatment of Healthcare Associated Infections (HAI) 
have a significant impact on the care pathways and hospital costs; one of the most 
diffused HAI is Clostridium Difficile (CDI). The study aimed to assess the CDI distri-
bution, related costs and possible areas of saving. MethOds: Patients admitted at 
the TorVergata University Hospital between January and December 2013 presenting a 
CDI diagnosis were identified by analysing the Microbiology Laboratory Information 
Flow. Turn-Around-Time(TAT) was used to assess the efficiency of diagnosis with 
cultural exam and PCR methodologies. Through the analysis of clinical records, the 
CDI distribution in hospital departments and DRGs were examined. The economic 
value associated to each admission was calculated. Results: In the considered 
period, 1769 CDI tests were performed. 752 were valid for the analysis, 170 tests (22%) 
were positive and corresponded to 94 admissions. The TAT analysis showed that the 
PCR allowed saving about three days, compared to the cultural exam. The incidence 
of CDI was 8.2cases per 10,000bed-days/patient. More than half of cases were in: 
General Medicine(27;29%); Gastroenterology(14;15%); casualty department(12;13%); 
Infectious Diseases, respiratory Medicine, onco-haematology(respectively9;10%). 
ALOS was 31.8days (between5-132). The five most frequent DRGs were: DRG-572.
Gastrointestinal and peritoneal infections(n= 10), DRG-576.Septicemia without 
questionnaires based on a 0-7 points Likert scale were delivered to n= 10 subacute 
stroke patients affected by upper limb hemiparesis and n= 23 physiotherapists using 
two different robotic systems (InMotion2, Interactive Motion Technologies, USA and 
Armeo Spring, Hocoma AG, Switzerland). The (i) perceived comfort and effectiveness 
of robot-assisted rehabilitation treatments and (ii) evaluation of human-robot inter-
action was investigated. An economic analysis of costs associated to the introduc-
tion of robotic technology into clinical practice was carried out as well. Results: 
Stroke patients consider the upper limb robot-assisted rehabilitation treatment as 
positive (mean score 5.80±0.89) and 96% of them consider it as safe. An higher score 
associated to the desire of continuing the robotic therapy (mean score 6.30±0.82) 
than that reported by physiotherapists (mean score 5.31±1.66) was found. Positive 
evaluations by patients on usefulness, satisfaction and desire to continue highlight 
the potential effectiveness of the robotic treatment. Results from physiotherapists 
confirm the positive attitude towards robotic technology (mean score 6.12±0.66), 
especially in terms of safety and satisfaction. Direct and indirect costs associated 
to upper limb robot-assisted rehabilitation treatment and traditional manual physi-
otherapy have been found to be comparable. cOnclusiOns: The perceived effec-
tiveness and acceptability of robotic technology for upper limb rehabilitation were 
positively evaluated both by stroke patients and physiotherapists. The initial high 
economic investment in robotic technology should be considered as associated to 
the optimization of healthcare resources. Further analyses on the effects of the 
robot-assisted rehabilitation treatments on the quality of life of patients have to 
be carried out through large multicentric RCTs.
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PREfERENCES fOR DRy POwDER INHALER ATTRIbUTES AMONG PATIENTS 
wITH ASTHMA AND CHRONIC ObSTRUCTIVE PULMONARy DISEASE fROM fIVE 
EUROPEAN COUNTRIES
Hawken NA1, Amri I2, Elmoctar Neine M3, Aballéa S3, Torvinen S4, Plich A4
1Creativ-Ceutical, Luxembourg, Luxembourg, 2Creativ-Ceutical, Tunis, Tunisia, 3Creativ-Ceutical, 
Paris, France, 4Teva Pharmaceuticals Europe B.V., Amsterdam, The Netherlands
Objectives: This study aimed at assessing patient preferences for different 
characteristics of Dry Powder Inhalers (DPIs) from patients with asthma and 
chronic obstructive pulmonary (COPD) disease in France, UK, Spain, Germany 
and Netherlands using the discrete choice experiment (DCE) method. MethOds: 
Attributes characterizing DPIs and attribute levels were defined using focus groups 
among asthma and COPD patients and interviews of health care professionals in 
France. Those attributes were ease of use, accurate and easy-to-read dose coun-
ter, dose confirmation, hygiene of the mouthpiece, flexibility of device handling 
and use with breathing difficulties. A fractional factorial design including 3 sets 
of 12 choices was created. Analyses were performed using a ranked ordered logit 
model. Interactions between attributes and asthma/COPD were tested. Results: 
Participants included 601 patients with asthma and 491 with COPD. Asthma and 
COPD patients were on average 43 and 53 years old respectively. Preferences of 
patients with asthma and COPD were largely similar, but the marginal utility of the 
cost attribute was higher in asthma patients, compared to COPD, in three countries. 
In all countries, marginal utilities were highest for ease of use and ability to use 
the inhaler with breathing difficulties. Estimates of willingness to pay (WTP) for an 
inhaler requiring one step to prepare a dose instead of four ranged from € 3.27 (95% 
CI: [2.23;4.32]) in asthma patients in Germany to € 15.14 [-82.43;112.72] in asthma/
Spain. The estimated WTP for ability to use with breathing difficulties ranged from 
€ 2.19 [1.10;3.28] in asthma patients in the Netherlands and € 13.68 [-117.77;145.12] 
in COPD/Spain. The marginal utility of the hygiene of the mouthpiece was not sig-
nificantly different from zero. cOnclusiOns: Despite differences in valuations 
of attributes between counties, two attributes were consistently found to be the 
most important: ease of use and ability to use the inhaler in case of difficulties 
breathing in.
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SUbjECTIVE OUTCOMES wITH bONE CONDUCTION AND MIDDLE EAR 
IMPLANTS fOR PATIENTS wTH CONDUCTIVE OR MIxED HEARING LOSS
Kosaner Kliess M, Zoehrer R, Schlick B, Mariacher M, Urban M
Vibrant MED-EL Hearing Technology GmbH, Innsbruck, Austria
Objectives: With the number of different hearing implants available for indi-
viduals with a conductive/mixed hearing loss (CMHL), it is becoming more and 
more important to demonstrate user needs and benefit, in particular for aiding in 
decision making. The aim of this study was to systematically review the subjective 
outcomes of different hearing implants for individuals with CMHL. MethOds: 
Several databases were searched using a comprehensive search strategy to iden-
tify studies published assessing subjective outcomes with unilateral middle ear 
implantations (MEI), percutaneous bone conduction implants (pBCI) and transcu-
taneous BCIs (tBCI). The search included papers in any language. Non-systematic 
reviews, case reports, letters, editorials; animal, in-vitro and laboratory studies 
and clinical studies with less than 5 cases were excluded. Results: Out of 670 
citations, 22 percutaneous and 7 transcutaneous BCI, plus 10 MEI publications were 
identified (total n= 1106). As many as 20 different questionnaires were applied. All 
devices lead to an improvement in HR-QOL when compared to the unaided condi-
tion. Using HR-QOL measures, outcomes with different pBCIs were in favour of the 
Ponto than the BAHA which was reflected in patient preferences. Comparison of 
pBCI with tBCI and MEI generally showed a similar distribution. Outcomes were 
relatively better with MEI than pBCI on one questionnaire. Outcomes of tBCIs and 
MEIs were also similar on HR-QOL measures, but were slightly in favour of the lat-
ter on a general-health QOL measure (G-QOL). The common HUI G-QOL measure 
was only available for pBCI and MEI users with any type of hearing loss, and results 
were similarly distributed. cOnclusiOns: There are many QOL measures for 
assessing hearing loss, however not many are sensitive at picking up differences 
between hearing implants. The studies identified in the literature, even though 
limited in number and quality, suggest health-related measures to be more sensi-
tive than general health measures.
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patients were conducted by cancer treating physicians in Germany/France/Spain/
Italy (EU4) and the UK; Data collection period was Jan-Dec 2013. Physicians 
were recruited from a geographically representative sample in each country. 
Approximately 10-25 eligible patients on usual care anti-cancer regimen were 
identified by each physician within the four-quarterly study observation-window. 
Physicians abstracted data on patient demographics, disease status, treatment 
patterns and biomarker status .The analysis focused on patients that were either 
tested (T) or not-tested (NT) for EGFRm in UK & EU4. Results: Approximately 
4800 mNSCLC patient-charts (UK~630/4EU~4170) were collected in 2013. 62%/62% 
were tested for EGFRm in the UK/4EU respectively. Mean age was: T-64yrs/NT-67yrs 
in both UK and EU4; proportion of patients who were male: T-56%/NT-64% in UK, 
T-61%/NT-78% in EU4. Proportion of patients who ‘never smoked’ was: T-29%/NT-9% 
in UK, T-23%/NT-12% in EU4. Time since disease diagnosis was: T-6mo/NT-10mo in 
UK, T-9mo/NT-9mo in EU4. Proportion of patients newly diagnosed: T-53%/NT-38% 
in UK, T-39%/NT-50% in EU4; % in relapse: T-24%/NT-50% in UK, T-32%/NT-19% in 
EU4. Proportion of patients with an ECOG score of > = 2 at the time of visit: T-4%/
NT-12% in UK, T-24%/NT-24% in EU4. cOnclusiOns: Distinct differences appear 
to exist within mNSCLC cohorts based on the EGFRm test status (T/NT) and geog-
raphy (UK/EU4). This warrants further research to understand the drivers behind 
the observed patterns (including the dynamics of respective national healthcare 
systems, access to biomarker testing, and physicians’ perception of patient suitabil-
ity for EGFRm testing) and to facilitate optimal care delivery that could eventually 
lead to the utilization of targeted oncology therapeutics to alleviate patient burden 
and improve outcomes.
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COMPARISON Of KRAS TESTED AND NOT-TESTED METASTATIC COLORECTAL 
CANCER (MCRC) PATIENT COHORTS IN EUROPE
Narayanan S1, Gallo F2
1Ipsos Healthcare, Washington, DC, USA, 2Ipsos Healthcare, New York, NY, USA
Objectives: Compare the characteristics of mCRC patients either tested or not for 
KRAS mutations in Europe in 2009 and 2013. MethOds: A multi-country retrospec-
tive medical chart-review of mCRC patients were conducted by cancer treating phy-
sicians in Germany/France/Spain/Italy (EU4) and the UK; Data collection period was 
2009-2013. Physicians were recruited from a geographically representative sample 
in each country. Approximately 10-25 eligible patients on usual care anti-cancer 
regimen were identified by each physician within each of the four-quarterly study 
observation-windows in respective years. Physicians abstracted data on patient 
demographics, disease status, treatment patterns and biomarker status .The 
analysis focused on patients that were either tested (T) or not (NT) for KRAS muta-
tion in 2009 and 2013. Results: Approximately 2350 mCRC patient-charts (UK~300/
EU4~2050) were abstracted in both 2013 and 2009. Proportion of patients who were 
male in 2013 were: T-62%/NT-60% in both UK and EU4; a directional shift towards 
more male patients in UK and towards more female patients in EU4 was noted 
from 2009 to 2013. Mean age was: T-55yrs/NT-66yrs in UK and T-64yrs/NT-66yrs in 
EU4 in 2009, while T-67yrs/NT-68yrs in UK and T-66yrs/NT-72yrs on EU4 in 2013. 
Majority (UK:56%/EU4:47%) of KRASm-tested patients were follow-up patients in 
2009 while the majority (UK:57%/EU4:42%) had relapse-status in 2013. Proportion 
of patients with an ECOG score of > = 1 at the time of visit was: T-68%/NT-77% in 
UK, T-60%/NT-66% in EU4 in 2009; T-82%/NT-76% in UK, T-74%/NT-79% in EU4 in 
2013. cOnclusiOns: Distinct differences appear to exist within mCRC cohorts 
based on the KRASm test status (T/NT), geography (UK/EU4) and the observation 
time-span (2009/2013). This warrants further research to understand the drivers 
behind the observed patterns and to facilitate optimal care deliverythat could even-
tually lead to the utilization of targeted oncology therapeutics to alleviate patient 
burden and improve outcomes.
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KNOwLEDGE ON THE APPROPRIATE TECHNIqUE Of bLOOS PRESSURE 
MONITORING AND LIMITS Of THE OSCILLOMETRIC bLOOD PRESSURE 
MEASUREMENT
Oláh A1, Horváth A1, Pakai A2, Boncz I1, Fullér N1, Knisz J1, Müller Á1, Szebeni-Kovács G1
1University of Pécs, Pécs, Hungary, 2University of Pécs, Zalaegerszeg, Hungary
Objectives: Prevalence of cardiovascular diseases is outsanding in Hungary. 
Incorrect data due to the inappropriate measurement of blood pressure and the 
inappropriate choice of the measurement tool cause a huge problem during clinical 
decision making. The aim of our exmination was to evaluate the nurses’ knowl-
edge on blood pressure measurement and analyse the precision of oscillometric 
blood pressure measurement compared to the mercurial blood pressure moni-
tor. MethOds: In our quantitative, cross-sectional study 96 nurses completed one 
questionnaire with only closed-ended questions and one with only open-ended 
questions. During the experimental study we measured the blood pressure of 16 
patients with tremor, 12 patients with arrhythmia and 32 patients with hypertonia. 
We used Microsoft Office Excel 2002 software to carry out descriptive statistics, 
χ 2-test and two-sample t-test (p< 0.05). Results: We found no significant differ-
ence between the two questionnaire types (p= 0.261), but we did find significant 
difference in the participating nurses’ level of knowledge (p> 0.001). Comparing 
the systolic values of patients with tremor showed significant difference between 
the mercurial- and the oscillometric blood pressure measurements (p= 0,003). We 
found no significant difference in case of the diastolic measures (p< 0.05). In case 
of patients with high blood pressure we found no significant difference regarding 
systolic values (p= 0.067), but we did find significant difference regarding the dias-
tolic values (p= 0.044). In case of patients with cardiac arrhythmia, no significant 
difference can be detected between the two measurements regarding the systolic 
(p= 0.352) and diastolic values (p= 0.274). cOnclusiOns: A necessary requirement 
of valid blood pressure measurement is to apply the appropriate blood pressure 
measurement protocol considering the influencing factors, and the application 
of aneroid blood pressure monitor (with approximately the same accuracy as the 
mercurial blood pressure monitor) with auscultation method.
mechanical ventilation≥ 96hours(n= 7); DRG-87.Respiratory insufficiency(n= 6); 
DRG-179.Inflammatory bowel diseases(n= 6); DRG-395.Red Blood Cells 
anomalies(n= 5), accounting for 215,414€ (29% of total). The economic value associ-
ated to whole admissions was 738,258€ . The most significant fluctuation of income 
within the same DRG was in the more frequent one: DRG-572(1,742€ -6,524€ ); and in 
the fifth DRG by frequency: DRG-395(3,394€ -15,124€ ). Differences are due to regional 
DRG monitoring. The higher economic values were associated to bowel, liver or 
bone marrow transplantation (DRGs480-481). cOnclusiOns: This pool of evidence 
allows developing standardised pathways for early diagnosis and treatment that 
help improving patients’ care, increasing hospital efficiency and bed occupancy, 
reduce length of stay and improve measures for infection control.
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REVIEw Of US MEDICARE SySTEM fOR REIMbURSEMENT Of NEw MEDICAL 
DEVICES
Battaglia S1, Fattore G2, Busca R1
1Medtronic International Trading Sàrl, Tolochenaz, Switzerland, 2SDA-Bocconi School of 
Management, Centre for Research in Healthcare Management (CERGAS), Milano, Italy
Objectives: The aim of this research is to assess US Medicare methodologies for 
the reimbursement of medical devices in hospital inpatient and outpatient ser-
vices. MethOds: A comprehensive literature search was conducted on PuBmed 
and US Department of Health and Human Services specific to Centers for Medicare 
and Medicaid Services (CMS). Results: CMS reimbursement structure is shaped by 
coverage, coding and payment arrangements with reimbursement playing a major 
role for commercially available devices and coding and coverage for devices under 
clinical studies. The payment mechanisms applied are defined by diagnosis related 
groups (DRG; hospital inpatient) and ambulatory payment classification (APC; hos-
pital outpatient) with an additional three separate short-term payment policies: 
new technology add on payments for in-patient services, transitional pass-through 
payments and new technology ambulatory payment classifications for outpatient 
services. Biannual reports are performed on existing and new policies for both inpa-
tient and outpatient provisions with updates on the reimbursement system retro-
spectively from 2-3 years prior to year of implementation. A case example in cardiac 
resynchronization therapies (CRT) in both inpatient and outpatient setting is used 
to illustrate the reimbursement mechanisms used by US Medicare. Medicare used 
a new technology add-on payment for 1 year (up to $16,262 supplemental funding) 
in addition to DRG payment (ranging from $81,950 to $104,092). To compare volume 
and estimated payments of CRT devices in the outpatient setting (2,358 outpatient 
compared to 21,920 inpatient) a separation of APC codes (with intent to create a 
new APC code) was conducted. The creation of a new APC code was refused with 
further restructuring of existing codes. cOnclusiOns: The results show regular 
and systematic collection of data to revise tariffs each year act as the main feature 
to allow for new medical technology to be accessible.
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PATTERNS Of USE Of TESTS TO MONITOR DISEASE ACTIVITy AMONG 
PATIENTS CURRENTLy TREATED fOR RELAPSING REMITTING MULTIPLE 
SCLEROSIS (RRMS) IN EUROPE
Narayanan S1, O’Meara PA2, White JL3, Chan JN3, Hooper RL3, Baynton EJ3
1Ipsos Healthcare, Washington, DC, USA, 2Ipsos Healthcare, New York, NY, USA, 3Ipsos 
Healthcare, London, UK
Objectives: To assess the patterns of use of tests to monitor disease activity/
progression among patients currently treated with disease modifying treatments 
(DMTs) for RRMS in EU. MethOds: A multi-center retrospective chart-review study 
of MS patients was conducted in EU (UK/France/Germany/Italy/Spain) to collect de-
identified data on diagnosis, clinical status, and disease management approaches. 
Healthcare providers (mostly neurologists) were screened for duration of practice 
(≥ 3yrs) and patient volume (≥ 15 MS patients/mo) and recruited from a large panel 
to be geographically representative in each country. Medical charts of next 10 con-
secutive MS patients were abstracted by each HCP. RRMS patients currently on DMTs 
were analyzed. Results: 1465 eligible RRMS patients treated with DMTs (UK:254, 
France:315, Germany:303, Italy:318, Spain:275) were included in this analysis. Time 
between MS diagnosis and initiation with a DMT was 8.3mo (range: 5.3(Germany) 
- 11.0(UK)). Proportion of patients on their first/second/third-or-more line DMT dur-
ing the study was 60%/29%/11%. Distribution of use of key tests to monitor disease 
activity/progression varied among RRMS patients on different lines of DMT (1st-
line/2nd-line/3rd-line-or-more: % patients assessed): Expanded Disability Status 
Scale (EDSS): 85/89/89; Neurological exam: 81/89/88; Gadolinium MRI: 59/70/80; T2 
MRI: 58/68/79; T1 MRI: 51/56/70; Brain atrophy: 11/18/24; Ambulation index: 11/15/23. 
For patients on 1st-line/2nd-line/3rd-line-or-more DMTs, mean # of Gd-enhanced 
lesions and # of T2 lesions were1.3/1.4/2.0 and 8.6/11.5/14.3 respectively. Proportion 
of patients with unknown Gd-enhanced lesions and unknown T2 lesions were (1st-
line/2nd-line/3rd-line-or-more): 35/27/22 and 33/28/26 respectively. cOnclusiOns: 
Neurological exam and EDSS were used among most patients, while prevalence 
of use of other tests varied and increased with patient progression through treat-
ment lines. At least one-fourth and one-fifth of patients across treatment lines had 
unknown T2 and gd-enhanced lesions respectively. Observed practice patterns may 
warrant further scrutiny to optimize care delivery and therapeutic interventions 
to alleviate disease burden.
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COMPARISON Of EPIDERMAL GROwTH fACTOR RECEPTOR (EGfR) TESTED AND 
NOT-TESTED METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC) PATIENT 
COHORTS IN EUROPE
Narayanan S1, Gallo F2
1Ipsos Healthcare, Washington, DC, USA, 2Ipsos Healthcare, New York, NY, USA
Objectives: Compare the characteristics of mNSCLC patients either tested or 
not for Human Epidermal Growth Factor Receptor 2 mutation (EGFRm/HER2) in 
Europe. MethOds: A multi-country retrospective medical chart-review of mNSCLC 
